keyword
https://read.qxmd.com/read/38496142/assessing-the-safety-and-efficacy-of-rivaroxaban-for-stroke-prevention-in-patients-with-atrial-fibrillation-a-systemic-review-and-meta-analysis
#21
REVIEW
Ghazala S Virk, Sana Javed, Raheel Chaudhry, Mustafa M Moazam, Arhum Mahmood, Faraz Mahmood, Mohammed Zaheer, Shahroz M Khan, Vedika Rajasekaran
An effective anticoagulation therapy is required for patients with atrial fibrillation because it presents a significant risk of stroke. The current study evaluates the relative safety as well as efficacy of rivaroxaban in patients who are diagnosed with atrial fibrillation. A thorough literature review of relevant databases was conducted, focusing on academic and clinical studies that were published from 2017 onward. Inclusion criteria comprised randomized controlled trials and other observational studies comparing the incidence of stroke and the safety index of rivaroxaban in atrial fibrillation...
February 2024: Curēus
https://read.qxmd.com/read/38494906/use-of-andexanet-alfa-for-factor-xa-inhibitor-reversal-in-us-verified-trauma-centers-a-national-survey
#22
JOURNAL ARTICLE
Charles Fasanya, Abenámar Arrillaga, Catherine Caronia, Lauren Rothburd, Tenzing Japhe, Younghee Hahn, Paul Joseph, Dajana Reci, Patricia Eckardt
Direct oral factor Xa inhibitors are replacing vitamin K-dependent antagonists as anticoagulation treatment in many clinical scenarios. Trauma centers are noting an increase in patients presenting on these medications. The 2018 Food and Drug Administration approval of andexanet alfa provides an alternative anticoagulation reversal. Barriers may limit utilization of new medications including a lack of grade 1A evidence supporting the use of prothrombin complex concentrate (PCC) versus andexanet alfa and cost...
2024: Clinical and Applied Thrombosis/hemostasis
https://read.qxmd.com/read/38493886/comparative-outcomes-of-peripheral-vascular-interventions-in-patients-on-chronic-anticoagulation-with-factor-xa-inhibitors-and-vitamin-k-antagonists
#23
JOURNAL ARTICLE
Joshua J Huttler, Dana Alameddine, Fachreza Aryo Damara, Paula Pinto- Rodriguez, Zhen Wu, Martin Slade, David Strosberg, Cassius Iyad Ochoa Chaar
OBJECTIVE: In patients undergoing revascularization for peripheral arterial disease (PAD), low-dose Factor Xa inhibitors (FXaI) taken with aspirin improved limb and cardiovascular outcomes compared to aspirin alone. Further, in atrial fibrillation and venous thromboembolism, FXaI are recommended over vitamin K antagonists (VKA) for chronic anticoagulation. While studies have evaluated different perioperative anticoagulation regimens in patients treated for PAD, the optimal regimen for chronic anticoagulation in patients with PAD undergoing PVI has not been determined...
March 15, 2024: Annals of Vascular Surgery
https://read.qxmd.com/read/38491267/outcomes-of-venous-thromboembolism-in-patients-with-inherited-thrombophilia-treated-with-direct-oral-anticoagulants-insights-from-the-riete-registry
#24
JOURNAL ARTICLE
Omri Cohen, Gili Kenet, Sarina Levy-Mendelovich, Inna Tzoran, Benjamin Brenner, Cristina De Ancos, Patricia López-Miguel, José F Varona, Judith Catella, Manuel Monreal
While direct oral anticoagulants (DOACs) are frequently used to treat venous thromboembolism (VTE), the outcomes of patients with inherited thrombophilia (IT) receiving DOACs for VTE remain understudied. We used data from the international RIETE registry to compare the rates of VTE recurrences, major bleeding, and mortality during anticoagulant treatment in VTE patients with and without IT, grouped by the use of DOACs or standard anticoagulant therapy. Among 103,818 enrolled patients, 21,089 (20.3%) were tested for IT, of whom 8422 (39...
March 16, 2024: Journal of Thrombosis and Thrombolysis
https://read.qxmd.com/read/38487677/drug-related-problems-associated-with-direct-oral-anticoagulants-an-observational-cross-sectional-study-of-medical-record-review-by-pharmacists-in-a-large-teaching-hospital
#25
JOURNAL ARTICLE
Melissa M Y Chow, Duke J J Chua, Vivian S Y Wong, Sin Y How, Sei K Koh, Xin Y Tay, Lai H Lee
BACKGROUND: Prescribing DOACs presents with challenges in the elderly and patients with renal and hepatic impairment. To mitigate safety risks, pharmacists have a role in detection, prevention, and resolution of DOAC-associated drug-related problems (DRPs). OBJECTIVES: To identify the types of DOAC-associated DRPs in patients on DOAC therapy and factors that predispose patients to DOAC-associated DRPs. METHODS: An observational cross-sectional study was conducted in SGH from January 1, 2017, to May 31, 2019, on patients prescribed with a DOAC (rivaroxaban, dabigatran, and apixaban)...
February 2024: Research and Practice in Thrombosis and Haemostasis
https://read.qxmd.com/read/38482394/characterization-of-antithrombotic-regimens-for-patients-with-nonvalvular-atrial-fibrillation-and-obesity-discharged-from-cardiology-wards
#26
JOURNAL ARTICLE
Stephanie O'Byrne, Kirsten Tangedal, Brandon Kennedy, William Semchuk
BACKGROUND: Despite data derived from observational studies, optimal anticoagulation strategies have yet to be established for patients with nonvalvular atrial fibrillation and obesity. OBJECTIVE: To describe direct oral anticoagulant (DOAC) regimens prescribed for adult patients with nonvalvular atrial fibrillation who weighed more than 120 kg. METHODS: This single-centre, retrospective cohort study, conducted in the Saskatchewan Health Authority - Regina Area, involved adult patients with body weight greater than 120 kg who had an indication for oral anticoagulation to treat nonvalvular atrial fibrillation and were discharged by a cardiologist between June 2019 and July 2021...
2024: Canadian Journal of Hospital Pharmacy
https://read.qxmd.com/read/38479723/total-shoulder-arthroplasty-in-patients-with-factor-v-leiden
#27
JOURNAL ARTICLE
Katie M Zehner, Joshua G Sanchez, Meera M Dhodapkar, Maxwell Modrak, Xuan Luo, Jonathan N Grauer
BACKGROUND: Anatomic and reverse total shoulder arthroplasty (TSA) are effective treatment options for end-stage glenohumeral osteoarthritis. However, consideration for pre-existing conditions must be taken into account. Factor V Leiden (FVL), the most common inherited thrombophilia, is one such condition that predisposes to a prothrombotic state and may affect perioperative and longer-term outcomes following TSA. METHODS: Adult patients undergoing primary TSA for osteoarthritis indication were identified in the 2010 through October 2021 PearlDiver M157 database...
March 11, 2024: Journal of Shoulder and Elbow Surgery
https://read.qxmd.com/read/38470020/half-dose-direct-oral-anticoagulation-versus-warfarin-for-atrial-fibrillation-following-cardiac-surgery
#28
JOURNAL ARTICLE
Sabet W Hashim, Susan Collazo, Amanda Greco, Jeff F Mather, Raymond G McKay
BACKGROUND: Optimal anticoagulation strategies have not been defined for patients with atrial fibrillation following cardiac surgery. METHODS: From a total cohort of 228 patients with pre-existing or new onset atrial fibrillation following coronary artery bypass grafting and/or valve surgery, we compared in-hospital and 30-day outcomes in 119 patients treated with low-dose aspirin and a half-dose direct oral anticoagulant (DOAC) versus 109 treated with low-dose aspirin and warfarin...
March 12, 2024: Journal of Cardiovascular Surgery
https://read.qxmd.com/read/38468994/anticoagulating-new-onset-atrial-fibrillation-after-covid-19-a-single-center-experience
#29
JOURNAL ARTICLE
Miles Babb, Kurt Stevenson
Anticoagulation (AC) strategy in new-onset atrial fibrillation (NOAF) secondary to other illnesses has not been broadly studied, and society-level guidance does not provide a strong recommendation regarding outpatient continuation upon discharge. Our study focused specifically on patients experiencing NOAF secondary to COVID-19. It sought to understand whether our facility's rounding prescribers were continuing patients on AC at discharge, the presence of arrhythmia at one-year follow-up, and to observe the risk of adverse outcomes in light of this unique precipitant...
February 2024: Curēus
https://read.qxmd.com/read/38468835/secondary-prophylaxis-of-venous-thromboembolism-vte-with-low-dose-apixaban-or-rivaroxaban-results-from-a-patient-population-with-more-than-2-years-of-median-follow-up
#30
JOURNAL ARTICLE
Alessandro Laganà, Giovanni Manfredi Assanto, Chiara Masucci, Mauro Passucci, Livia Donzelli, Alessandra Serrao, Erminia Baldacci, Cristina Santoro, Antonio Chistolini
BACKGROUND: Direct oral anticoagulants (DOACs) are widely used for the treatment and secondary prophylaxis of venous thromboembolism (VTE). Nowadays, DOACs represent the gold standard for long-term anticoagulation, with low-intensity DOACs administration becoming increasingly used worldwide in such scenario. Albeit low-intensity apixaban and rivaroxaban are approved for clinical usage as secondary VTE prophylaxis, there are few literature data regarding their efficacy and safety with a long follow-up...
2024: Mediterranean Journal of Hematology and Infectious Diseases
https://read.qxmd.com/read/38468834/how-the-hemostasis-laboratory-can-help-clinicians-to-manage-patients-on-oral-anticoagulants
#31
REVIEW
Armando Tripodi, Marigrazia Clerici, Erica Scalambrino, Pasquale Agosti, Paolo Bucciarelli, Flora Peyvandi
Oral anticoagulants are widely used to treat or prevent cardiovascular diseases in millions of patients worldwide. They are the drugs of choice for stroke prevention and systemic embolism in patients with non-valvular atrial fibrillation and prosthetic heart valves, as well as for treatment/prevention of venous thromboembolism. Oral anticoagulants include vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs). The hemostasis laboratory plays a crucial role in the management of treated patients, spanning from dose adjustment based on laboratory testing that applies to VKAs to the measurement of drug concentrations in special situations that apply to DOACs...
2024: Mediterranean Journal of Hematology and Infectious Diseases
https://read.qxmd.com/read/38467144/direct-oral-anticoagulants-for-pulmonary-embolism
#32
JOURNAL ARTICLE
Roberto Pizzi, Ludovica Anna Cimini, Walter Ageno, Cecilia Becattini
Venous thromboembolism (VTE) is the third most common cardiovascular disease. For most patients, the standard of treatment has long consisted on low-molecular-weight heparin followed by vitamin K antagonists, but a number of clinical trials and, subsequently, post-marketing studies have shown that direct oral anticoagulants (DOACs) with or without lead-in heparin therapy are effective alternatives with fewer adverse effects. This evidence has led to important changes in the guidelines on the treatment of VTE, including pulmonary embolism (PE), with the DOACs being now recommended as the first therapeutic choice...
March 11, 2024: Hämostaseologie
https://read.qxmd.com/read/38461613/fragility-and-long-term-clinical-outcomes-in-patients-with-venous-thromboembolism-receiving-direct-oral-anticoagulants-from-the-command-vte-registry-2
#33
JOURNAL ARTICLE
Yoshito Ogihara, Yugo Yamashita, Takeshi Morimoto, Ryuki Chatani, Kazuhisa Kaneda, Yuji Nishimoto, Nobutaka Ikeda, Yohei Kobayashi, Satoshi Ikeda, Kitae Kim, Moriaki Inoko, Toru Takase, Shuhei Tsuji, Maki Oi, Takuma Takada, Kazunori Otsui, Jiro Sakamoto, Takeshi Inoue, Shunsuke Usami, Po-Min Chen, Kiyonori Togi, Norimichi Koitabashi, Seiichi Hiramori, Kosuke Doi, Hiroshi Mabuchi, Yoshiaki Tsuyuki, Koichiro Murata, Kensuke Takabayashi, Hisato Nakai, Daisuke Sueta, Wataru Shioyama, Tomohiro Dohke, Toru Sato, Ryusuke Nishikawa, Takeshi Kimura, Kaoru Dohi
INTRODUCTION: There is limited data on the safety of direct oral anticoagulants (DOACs) in fragile patients with venous thromboembolism (VTE). MATERIALS AND METHODS: We used the COMMAND VTE Registry-2 enrolling patients with acute symptomatic VTE. The study population consisted of 3928 patients receiving DOACs, who were divided into fragile (2136 patients) and non-fragile groups (1792 patients). Fragility was defined as patients of age ≥ 75 years, creatinine clearance level ≤ 50 ml/min, and/or body weight ≤ 50 kg...
February 29, 2024: Thrombosis Research
https://read.qxmd.com/read/38458580/atrial-thrombosis-prevalence-before-cardioversion-or-catheter-ablation-of-atrial-fibrillation-an-updated-systematic-review-and-meta-analysis-of-direct-oral-anticoagulants-versus-vitamin-k-antagonists
#34
JOURNAL ARTICLE
Federica Troisi, Pietro Guida, Nicola Vitulano, Federico Quadrini, Antonio Di Monaco, Giuseppe Patti, Massimo Grimaldi
Left atrial or left atrial appendage thrombosis (LAT) is contraindicated for cardiac ablation (CA) or cardioversion (CV) of atrial fibrillation (AF). This study was aimed to compare the frequency of LAT detected by transesophageal echocardiography (TEE) before CA or CV in patients with AF treated with direct oral anticoagulants (DOACs) or vitamin K antagonists (VKAs). We searched PubMed, Scopus, Web of Science, and Cochran Library databases from inception through July 13, 2023 to select studies reporting data on LAT identification before CA or CV using TEE in patients with AF treated with DOACs or VKAs...
March 7, 2024: American Journal of Cardiology
https://read.qxmd.com/read/38458228/pearls-and-pitfalls-in-the-measurement-of-direct-oral-anticoagulants
#35
JOURNAL ARTICLE
Giuseppe Lippi, Emmanuel J Favaloro
Due to their widespread use, testing for direct oral anticoagulants (DOACs) has become urgent in certain clinical situations. Screening based on widely available, rapid, and simple hemostasis assays such as prothrombin time, activated partial thromboplastin time, or even diluted Russel Viper venom time may provide sufficient evidence of "over-coagulation" and could be used "in small/peripheral/spoke laboratories" as an emergency strategy, but is not thought to be reliable for driving clinical decision making...
March 8, 2024: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/38449356/real-world-experience-of-direct-oral-anticoagulant-use-in-a-single-pediatric-center
#36
JOURNAL ARTICLE
Gianna G Valenti, Cynthia Sabo, Michelle Hyde, Madhvi Rajpurkar
BACKGROUND: Pediatric venous thromboembolism has increased by 130%-200%, specifically in hospitalized children, and direct oral anticoagulants (DOACs) offer several therapeutic advantages. METHODS: This study aims to evaluate the real-world epidemiological and outcome data from a retrospective review of pediatric patients treated with DOACs from January 1, 2013 to December 31, 2022. In this single-center, IRB-approved study, 65 patients were identified and analyzed using SPSS statistical software, and a descriptive statistical analysis was conducted...
March 6, 2024: Pediatric Blood & Cancer
https://read.qxmd.com/read/38448081/epicardial-left-atrial-appendage-clipping-versus-direct-oral-anticoagulant-to-reduce-stroke-risk-in-non-paroxysmal-atrial-fibrillation-laa-clip-rationale-design-and-study-protocol-for-a-multicentre-randomised-controlled-trial
#37
JOURNAL ARTICLE
Chunyu Yu, Haojie Li, Chuxiang Lei, Yang Wang, Sipeng Chen, Yan Zhao, Zhe Zheng
INTRODUCTION: The prevalence of atrial fibrillation (AF) is increasing globally, and stroke prevention is the key to reduce the morbidity and mortality related to AF. Currently, direct oral anticoagulants (DOACs) are the primary options for stroke prevention, while it increases risk of bleeding. Left atrial appendage (LAA) is suspected as a vital source of cerebral emboli and may lead to ischaemic stroke, and thoracoscopic LAA clipping procedure provides an alternative option for stroke prevention in high-risk patients...
March 5, 2024: BMJ Open
https://read.qxmd.com/read/38443337/being-precise-with-anticoagulation-to-reduce-adverse-drug-reactions-are-we-there-yet
#38
REVIEW
Benjamin Cross, Richard M Turner, J Eunice Zhang, Munir Pirmohamed
Anticoagulants are potent therapeutics widely used in medical and surgical settings, and the amount spent on anticoagulation is rising. Although warfarin remains a widely prescribed oral anticoagulant, prescriptions of direct oral anticoagulants (DOACs) have increased rapidly. Heparin-based parenteral anticoagulants include both unfractionated and low molecular weight heparins (LMWHs). In clinical practice, anticoagulants are generally well tolerated, although interindividual variability in response is apparent...
March 5, 2024: Pharmacogenomics Journal
https://read.qxmd.com/read/38432979/efficacy-and-feasibility-of-edoxaban-therapy-without-prior-parenteral-anticoagulants-in-patients-with-venous-thromboembolism
#39
JOURNAL ARTICLE
Naoya Kataoka, Teruhiko Imamura
No abstract text is available yet for this article.
March 4, 2024: Internal Medicine
https://read.qxmd.com/read/38430266/recommendations-for-the-safe-use-of-direct-oral-anticoagulants-in-patients-with-cirrhosis-based-on-a-systematic-review-of-pharmacokinetic-pharmacodynamic-and-safety-data
#40
REVIEW
Maaike M E Diesveld, Daniëlle W M Jacobs- Pijnenburg, Rianne A Weersink, Ina Barzel, Joost P H Drenth, Ton Lisman, Herold J Metselaar, Margje H Monster-Simons, Midas B Mulder, Eline Okel, Katja Taxis, Sander D Borgsteede
PURPOSE: The popularity of direct oral anticoagulants (DOACs) is increasing among patients with cirrhosis. Cirrhosis has a major impact on the pharmacokinetics of drugs, potentially increasing adverse events. Safe use of drugs in cirrhosis requires a diligent risk-benefit analysis. The aim of this study is to develop practice recommendations for safe use of DOACs in cirrhosis based on a systematic review of pharmacokinetic, pharmacodynamic and safety data. METHODS: We conducted a systematic literature search to identify studies on pharmacokinetics, pharmacodynamics and safety of DOACs in cirrhosis...
March 2, 2024: European Journal of Clinical Pharmacology
keyword
keyword
64007
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.